Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study

Table 3 Changes in signs and symptoms of psoriatic arthritis between baseline and week 24

Characteristic	Baseline	Week 24	P value
TJC 78 (median, IQR)	10 (6, 16.5)	1 (0, 3.5)	< 0.001**
SJC 76 (median, IQR), (mean ± SD)	4 (3, 7), 5.1 ± 2.5	0 (0, 0)†, 0.2 ± 0.4	< 0.001**
DAS28-ESR (median, IQR)	4.93 (4.08, 5.74)	2.93 (2.01, 3.70)	0.001**
DAPSA (median, IQR)	27.55 (22.53, 38.35)	5.73 (3.63, 3.70)	< 0.001**
PASI (median, IQR)	0.4 (0.2, 2.3)	0.1 (0, 1.3)	0.062
BSA% (median, IQR)	0.3 (0.2, 1.5)	0.2 (0, 1.9)	0.325
ACR20	-	82.4%	-
ACR50	-	52.9%	-
ACR70	-	35.3%	-
EULAR moderate	-	68.8%	-
EULAR good	-	25.0%	-
PSARC	-	88.2%	-
DAPSA minor#	-	11.8%	-
DAPSA moderate#	-	29.4%	-
DAPSA good#	-	35.3%	-
DAPSA high##	-	0%	-
DAPSA moderate##	-	17.6%	-
DAPSA low##	-	52.9%	-
DAPSA remission##	-	29.4%	-
MDA	-	46.2%	-

ACR American College of Rheumatology, BSA% percent body surface area, DAPSA disease activity in psoriatic arthritis score, DAS28-ESR disease activity score 28 based on erythrocyte sedimentation rate, EULAR European League Against Rheumatism, IQR interquartile range, MDA minimal disease activity, PASI psoriasis area and severity index, PsARC psoriatic arthritis response criteria, SJC swollen joint count, TJC tender joint count. #Minor (change ≥50%), moderate (≥75%), good (≥85%). ##Remission (DAPSA ≤4), low (>4 and ≤14), moderate (>14 and ≤28), high (>28). †Additionally reported as mean and standard deviation (mean ± standar deviation) because median was equal to zero. Data are based on 17 psoriatic arthritis patients with complete baseline and 24 week data. Wilcoxon signed-rank test. *P ≤0.05, **P ≤0.01

ISSN: 1478-6362